Evidence Table N2. CONTINUOUS outcomes for class OTHER.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	N.01.02			**Gugulipid**		**Tetracycline**		
325 ↑ Parallel	N=20 Sev	**Inflammatory change (%)**	Mid (12)	Percent change: -68		Percent change: -65		**NS**
		Non-inflammatory change (%)	Mid (12)	Percent change: -12		Percent change: -11		**NS**
	N.01.03			**Isolutrol**		**Benzoyl peroxide**		
94 Parallel	N=70 Mild/mod	**Inflammatory (count)** Count location: Face. Baseline counts: 24 (Target) / 33 (Comparator)	Short (4)	Percent Change*: -16		Percent Change*: -34		
		Non-inflammatory (count) Count location: Face.	Short (4)	Raw count: 20		Raw count: 17		
		Inflammatory (count) Count location: Face. Baseline counts: 24 (Target) / 33 (Comparator)	Mid (12)	Percent Change*: -33	*.06*	Percent Change*: -67	*.003*	
		Non-inflammatory (count)	Mid (12)	Raw count: 17	*.0002*	Raw count: 12	*.0001*	
	N.01.05			**Tea tree oil**		**Benzoyl peroxide**		
18 ↑ Parallel	N=124 Mod	**Inflammatory (count)** Count location: 3 + c face. Baseline counts: 35 (Target) / 38 (Comparator)	Short (4)	Percent Change*: -38		Percent Change*: -50		**0.05**
		Non-inflammatory (count) Count location: 3 + c face.	Short (4)	Raw count: 32		Raw count: 25		**NS**
		Inflammatory (count) Count location: 3 + c face. Baseline counts: 35 (Target) / 38 (Comparator)	Mid (12)	Percent Change*: -68	*.001*	Percent Change*: -47	*.001*	**0.001**
		Non-inflammatory (count) Count location: 3 + c face.	Mid (12)	Raw count: 15	*.05*	Raw count: 16	*.01*	**NS**
	N.02.01			**Clobetasol**		**Vehicle**		
175 ↑ Parallel Mod	N=11 split face	**Inflammatory (count)** Baseline counts: 31 (Target) / 33 (Comparator)	Short (3)	Percent Change*: 00		Percent Change*: 00		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
	N.04.02			**Hydrocortisone + buttoxethyl nicotinate + chloramp**		**Vehicle**		
224 ↑ N=120 Cross-over Mild/mod/sev		**Comedones reduction percentage change (%)**	Short (5)	Percent change: -33		Percent change: -93		**NS**
		Inter-group difference papule % change (%)	Mid (10)	Percent change: -52		Percent change: 65		**0.01**
		Inter-group difference pustule % change (%)	Mid (10)	Percent change: 51		Percent change: 90		**NS**
	N.04.03			**Chloramphenicol + hydrocortisone + sulfur**		**Chloramphenicol + sulfur**		
142 N=50 Parallel Mild/mod		**Severity (score)** Count location: 3 in square.	Short (4)	Measure: 26		Measure: 33		**NS**
		Total lesions change (%)	Short (4)	Percent change: -71		Percent change: -57		**NS**
		Severity (score)	Mid (12)	Measure: 11		Measure: 8		**NS**
		Total lesions change (%)	Mid (12)	Percent change: -87		Percent change: -89		**NS**
	N.04.04			**Chloramphenicol + hydrocortisone + sulfur**		**Hydrocortisone + sulfur**		
115 ↑ N=37 Parallel		**Severity change (fraser %)**	Short (4)	Measure: -48	*.001*	Measure: -28	*.001*	**0.03**
		Severity change (fraser %)	Mid (12)	Measure: -64	*.001*	Measure: -60	*.001*	**NS**
	N.04.05			**Chloramphenicol + hydrocortisone + sulfur**		**Benzoyl peroxide**		
75 ↑ N=48 Parallel Mod		**Inflammatory (count)** Baseline counts: 21 (Target) / 23 (Comparator)	Short (4)	Percent Change*: -19	*NS*	Percent Change*: -35	*.05*	**NS***
		Non-inflammatory (count) Baseline counts: 40 (Target) / 37 (Comparator)	Short (4)	Percent Change*: 00	*NS*	Percent Change*: -30	*.01*	**NS***
		Overall assessment/patient (vas)	Short (4)	Measure: 17 (3.)	*.05*	Measure: 14 (4.)	*.05*	**NS***
		Severity (leeds)	Short (4)	Measure: 2 (0.2)	*.01*	Measure: 2 (0.3)	*.01*	**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
75 ↑ Parallel	N=48 Mod	**Inflammatory (count)** Baseline counts: 21 (Target) / 23 (Comparator)	Mid (12)	Percent Change*: -38	*.01*	Percent Change*: -37	*.01*	**NS***
		Non-inflammatory (count) Baseline counts: 40 (Target) / 37 (Comparator)	Mid (12)	Percent Change*: -30	*NS*	Percent Change*: -38	*.01*	**NS***
		Overall assessment/patient (vas)	Mid (12)	Measure: 28 (5.)	*.01*	Measure: 25 (8.)	*.01*	**NS***
		Severity (leeds)	Mid (12)	Measure: 1 (0.2)	*.01*	Measure: 2 (0.2)	*.01*	**NS***
	N.05.03			**Fulguration**		**Tretinoin**		
31 Parallel Mild	N=11 split face	**Closed comedone change (%)** Count location: Symmetric area of face.	Short (4)	Percent change: -92 (8.)		Percent change: -10 (21.)		**0.005**
	N.05.04			**Fulguration**		**Electrocautery**		
32 Parallel Mild	N=12 split face	**Large comedone change (%)** Count location: Symmetric area of face.	Short (4)	Percent change: -46 (23.)		Percent change: -73 (12.)		**0.025**
		Small comedones change (%)	Short (4)	Percent change: -76 (13.)		Percent change: -82 (11.)		**NS**
	N.07.01			**Zinc**		**Vehicle**		
64 Parallel	N=30 Mild/mod	**Irritation (score)**	Short (6)	Measure: 2		Measure: 1		**0.05**
		Severity (michaelsson) Count location: Unspecified.	Short (6)	Measure: 98		Measure: 100		**NS**
		Irritation (score)	Mid (12)	Measure: 1		Measure: 1		**0.05**
		Severity (michaelsson) Count location: Unspecified.	Mid (12)	Measure: 94		Measure: 98		**NS**
	N.07.02			**Zinc**		**Placebo**		
91 ↑ Parallel	N=66 Mod	**Inflammatory severity (dreno)** Between P-value: inappropriate test.	Short (4)	Measure: 34 (14.8)		Measure: 46 (28.7)		**NS**
		Inflammatory severity (dreno)	Mid (8)	Measure: 27 (14.9)		Measure: 47 (29.8)		**0.02**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
	N.07.02			Zinc sulfate		Placebo		
341 ↑ Parallel	N=52 Mild/mod	**Comedones (count)** Count location: 2 cm worst. Baseline counts: 12 (Target) / 13 (Comparator)	Short (6)	Percent Change*: -50		Percent Change*: -15		**NS**
		Cysts (count) Count location: Face & submandibular. Baseline counts: 0 (Target) / 0 (Comparator)	Short (6)	Percent Change*: 00		Percent Change*: -37		**NS**
		Papules (count) Count location: Face & submandibular. Baseline counts: 18 (Target) / 21 (Comparator)	Short (6)	Percent Change*: -42		Percent Change*: -19		**NS**
		Pustules (count) Count location: Face & submandibular. Baseline counts: 9 (Target) / 13 (Comparator)	Short (6)	Percent Change*: -49		Percent Change*: -52		**NS**
		Severity (michaelsson)	Short (6)	Measure: 21		Measure: 36		**NS**
211 Parallel	N=59 Mild/mod/sev	**Severity change (pillsbury %)**	Short (6)	Measure: -33 (25.)		Measure: -20 (25.)		**0.007**
341 ↑ Parallel	N=52 Mild/mod	**Comedones (count)** Count location: 2 cm worst. Baseline counts: 12 (Target) / 13 (Comparator)	Mid (12)	Percent Change*: -50		Percent Change*: -38		**NS**
		Cysts (count) Count location: Face & submandibular. Baseline counts: 0 (Target) / 0 (Comparator)	Mid (12)	Percent Change*: 00		Percent Change*: -33		**NS**
		Papules (count) Count location: Face & submandibular. Baseline counts: 18 (Target) / 21 (Comparator)	Mid (12)	Percent Change*: -48		Percent Change*: -37		**NS**
		Pustules (count) Count location: Face & submandibular. Baseline counts: 9 (Target) / 13 (Comparator)	Mid (12)	Percent Change*: -37		Percent Change*: 02		**NS**
3 Parallel	N=42	**Severity (agrawal)**	Mid (12)	Measure: 43 (20.8)		Measure: 44 (40.8)		**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
341 ↑ Parallel	N=52 Mild/mod	**Severity (michaelsson)**	Mid (12)	Measure: 25 (21.)		Measure: 44 (32.)		**NS**
	N.07.02			**Zinc sulfate**		**Vehicle**		
342 ↑ Parallel	N=39 Mod	**Infiltrates (count)** Baseline counts: 6 (Target) / 3 (Comparator)	Short (4)	Percent Change*: 06	*NS*	Percent Change*: 03	*NS*	**NS**
		Papules (count) Baseline counts: 28 (Target) / 41 (Comparator)	Short (4)	Percent Change*: -27	*.05*	Percent Change*: -34	*.05*	**NS**
		Pustules (count) Baseline counts: 10 (Target) / 7 (Comparator)	Short (4)	Percent Change*: -42	*.05*	Percent Change*: -51	*.05*	**NS**
259 ↓ Parallel	N=30 Mild/mod	**Closed comedones (count)** Baseline counts: 19 (Target) / 39 (Comparator)	Short (6)	Percent Change*: -15	*NS*	Percent Change*: -51	*NS*	**NS**
336 ↑ Parallel	N=56 Mod	**Cysts (count)** Count location: Well defined regions. Baseline counts: 1 (Target) / 1 (Comparator)	Short (6)	Percent Change*: -04	*.001*	Percent Change*: -02	*NS*	**NS***
		Infiltrates (count) Count location: Well defined regions. Baseline counts: 2 (Target) / 1 (Comparator)	Short (6)	Percent Change*: -13	*.001*	Percent Change*: 171	*.05*	**NS***
259 ↓ Parallel	N=30 Mild/mod	**Open comedones (count)** Baseline counts: 22 (Target) / 40 (Comparator)	Short (6)	Percent Change*: -62	*NS*	Percent Change*: -68	*NS*	**NS**
336 ↑ Parallel	N=56 Mod	**Papules (count)** Count location: Well defined regions. Baseline counts: 29 (Target) / 19 (Comparator)	Short (6)	Percent Change*: -39	*NS*	Percent Change*: 05	*NS*	**NS***
259 ↓ Parallel	N=30 Mild/mod	**Papules (count)** Baseline counts: 14 (Target) / 16 (Comparator)	Short (6)	Percent Change*: -25	*NS*	Percent Change*: -48	*NS*	**NS**
		Pustules (count) Baseline counts: 4 (Target) / 2 (Comparator)	Short (6)	Percent Change*: -33	*NS*	Percent Change*: 87	*NS*	**NS**
336 ↑ Parallel	N=56 Mod	**Pustules (count)** Count location: Well defined regions. Baseline counts: 5 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -43	*NS*	Percent Change*: -22	*NS*	**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
259 ↓ N=30 Parallel Mild/mod		**Closed comedones (count)** Baseline counts: 19 (Target) / 39 (Comparator)	Mid (12)	Percent Change*: -34	*NS*	Percent Change*: -45	*NS*	**NS**
342 ↑ N=39 Parallel Mod		**Infiltrates (count)** Baseline counts: 6 (Target) / 3 (Comparator)	Mid (12)	Percent Change*: -18	*NS*	Percent Change*: -27	*NS*	**NS**
259 ↓ N=30 Parallel Mild/mod		**Open comedones (count)** Baseline counts: 22 (Target) / 40 (Comparator)	Mid (12)	Percent Change*: -64	*NS*	Percent Change*: -52	*NS*	**NS**
		Papules (count) Baseline counts: 14 (Target) / 16 (Comparator)	Mid (12)	Percent Change*: -63	*NS*	Percent Change*: -63	*NS*	**NS**
342 ↑ N=39 Parallel Mod		**Papules (count)** Baseline counts: 28 (Target) / 41 (Comparator)	Mid (12)	Percent Change*: -54	*.01*	Percent Change*: -47	*.05*	**NS**
259 ↓ N=30 Parallel Mild/mod		**Pustules (count)** Baseline counts: 4 (Target) / 2 (Comparator)	Mid (12)	Percent Change*: -62	*NS*	Percent Change*: -25	*NS*	**NS**
342 ↑ N=39 Parallel Mod		**Pustules (count)** Baseline counts: 10 (Target) / 7 (Comparator)	Mid (12)	Percent Change*: -05	*NS*	Percent Change*: -52	*.05*	**NS**
	N.07.02			**Zinc sulfur**		**Placebo**		
133 ↑ N=59 Parallel Mod		**Comedones change (count)** Count location: Above jawline. Baseline counts: 39 (Target) / 41 (Comparator)	Short (6)	Percent change*: -36	*.001*	Percent change*: -40	*.01*	**NS**
		Papules change (count) Count location: Above jawline. Baseline counts: 13 (Target) / 12 (Comparator)	Short (6)	Percent change*: -40	*.001*	Percent change*: -23	*.01*	**NS**
		Pustules change (count)	Short (6)	Percent change*: -24	*.05*	Percent change*: 03	*NS*	**NS**
		Severity change (% michaelsson)	Short (6)	Measure: -33 (26.)	*.001*	Measure: -18 (33.)	*.01*	**0.01**
		Severity change (michaelsson)	Short (6)	Measure: -19 (17.7)	*.001*	Measure: -11 (12.3)	*.01*	**0.01**
	N.07.03			**Zinc sulfate**		**Oxytetracycline**		
232 ↑ N=40 Parallel Mod/sev		**Comedones change (count)**	Mid (12)	Change: -25 (25.7)		Change: -44 (52.6)		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
232 ↑ N=40 Parallel Mod/sev		**Comedones severity change (michaelsson difference)**	Mid (12)	Measure: -14 (13.9)		Measure: -24 (29.6)		**NS**
		Overall change/patient	Mid (12)	Measure: 2		Measure: 2		
		Overall change/physician	Mid (12)	Measure: 2		Measure: 2		
		Papules change (count)	Mid (12)	Change: -17 (16.9)		Change: -11 (14.)		**NS**
		Papules severity change (michaelsson difference)	Mid (12)	Measure: -20 (18.7)		Measure: -14 (15.2)		**NS**
		Pustules change (count)	Mid (12)	Change: -6 (5.6)		Change: -3 (4.3)		**NS**
		Pustules severity change (michaelsson difference)	Mid (12)	Measure: -13 (14.3)		Measure: -8 (10.1)		**NS**
		Total severity change/photo (michaelsson)	Mid (12)	Measure: 1		Measure: 1		**NS**
	N.07.03			**Zinc sulfate/citrate complex**		**Tetracycline**		
74 ↓ N=48 Parallel Mod		**Nodules (count)** Baseline counts: 2 (Target) / 3 (Comparator)	Short (4)	Percent Change*: -29	*NS*	Percent Change*: 35	*NS*	**NS***
		Non-inflammatory (count) Baseline counts: 45 (Target) / 80 (Comparator)	Short (4)	Percent Change*: -02	*NS*	Percent Change*: -08	*NS*	**NS***
		Overall change/patient (vas)	Short (4)	Measure: 14 (5.)	*NS*	Measure: 10 (6.)	*NS*	**NS***
		Papules (count) Baseline counts: 30 (Target) / 41 (Comparator)	Short (4)	Percent Change*: 03	*NS*	Percent Change*: -29	*NS*	**NS***
		Pustules (count) Baseline counts: 12 (Target) / 13 (Comparator)	Short (4)	Percent Change*: -25	*NS*	Percent Change*: -38	*NS*	**NS***
		Severity (burton)	Short (4)	Measure: 3 (0.2)	*NS*	Measure: 3 (0.2)	*NS*	**NS***
		Nodules (count) Baseline counts: 2 (Target) / 3 (Comparator)	Mid (12)	Percent Change*: -13	*NS*	Percent Change*: -50	*NS*	**NS***
		Non-inflammatory (count) Baseline counts: 45 (Target) / 80 (Comparator)	Mid (12)	Percent Change*: -11	*NS*	Percent Change*: -40	*.01*	**NS***
		Overall change/patient (vas)	Mid (12)	Measure: 15 (4.)	*NS*	Measure: 28 (5.)	*.01*	**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
74 ↓ N=48 Parallel Mod		**Papules (count)** Baseline counts: 30 (Target) / 41 (Comparator)	Mid (12)	Percent Change*: -13	*NS*	Percent Change*: -49	*.01*	**NS***
		Pustules (count) Baseline counts: 12 (Target) / 13 (Comparator)	Mid (12)	Percent Change*: -33	*.05*	Percent Change*: -46	*.01*	**NS***
		Severity (burton)	Mid (12)	Measure: 3 (0.1)	*NS*	Measure: 2 (0.1)	*.01*	**.001***
	N.08.01			**Erythromycin + zinc**		**Vehicle**		
301 ↓ N=73 Parallel Mod		**Comedones (count)** Count location: Face. Baseline counts: 33 (Target) / 29 (Comparator)	Short (6)	Percent Change*: -61		Percent Change*: -38		**0.05**
		Inflammatory (count) Count location: Face. Baseline counts: 20 (Target) / 28 (Comparator)	Short (6)	Percent Change*: -65		Percent Change*: -25		**0.01**
		Severity (cook) Count location: Face.	Short (6)	Measure: 3	*.05*	Measure: 5		**0.05**
		Severity change (cook)	Short (6)	Measure: -2		Measure: -1		
		Severity (cook)	Mid (10)	Measure: 2		Measure: 5		**0.05**
		Comedones (count) Count location: Face. Baseline counts: 33 (Target) / 29 (Comparator)	Mid (12)	Percent Change*: -61		Percent Change*: -48		
		Inflammatory (count) Count location: Face. Baseline counts: 20 (Target) / 28 (Comparator)	Mid (12)	Percent Change*: -73		Percent Change*: -46		**0.01**
		Severity change (cook) Count location: Face.	Mid (12)	Measure: -3		Measure: -1		**0.001**
	N.08.01			**Zinc + erythromycin**		**Vehicle**		
321 N=22 Parallel Mild/mod		**Inflammatory change (%)** Count location: Entire face.	Short (4)	Percent change: -55 (16.)		Percent change: -29 (16.)		**NS**
		Inflammatory change (%)	Mid (10)	Percent change: -60 (38.)		Percent change: -12 (63.)		**0.05**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	N.08.02			**Erythromycin + zinc**		**Erythromycin**		
147 ↑ N=122 Parallel Mod		**Comedones change (%)**	Short (4)	Percent change: -35		Percent change: -25		**NS**
		Inflammatory change (%) Count location: Face.	Short (4)	Percent change: -62		Percent change: -42		**0.001**
		Severity (cook)	Short (4)	Measure: 3		Measure: 3		**NS**
		Comedones change (%)	Mid (12)	Percent change: -62		Percent change: -40		**0.001**
		Inflammatory change (%)	Mid (12)	Percent change: -85		Percent change: -48		**0.001**
		Macules (count) Count location: Face. Baseline counts: 9 (Target) / 9 (Comparator)	Mid (12)	Percent Change*: -36	*.01*	Percent Change*: 00	*.02*	
		Nodules (count) Count location: Face. Baseline counts: 1 (Target) / 1 (Comparator)	Mid (12)	Percent Change*: -100	*.01*	Percent Change*: -60	*NS*	
		Severity (cook) Count location: Face.	Mid (12)	Measure: 2		Measure: 3		**0.001**
	N.08.02			**Erythromycin + zinc acetate**		**Erythromycin**		
28 ↑ N=45 Parallel Mild/mod		**Inflammatory (count)** Baseline counts: 57 (Target) / 54 (Comparator)	Short (4)	Percent Change*: -25	*.001*	Percent Change*: -35	*.01*	**NS***
		Non-inflammatory (count) Baseline counts: 55 (Target) / 52 (Comparator)	Short (4)	Percent Change*: -27	*.01*	Percent Change*: -23	*.01*	**NS***
		Severity (leeds)	Short (4)	Measure: 1 (0.5)	*.001*	Measure: 0 (0.5)	*.001*	**NS***
		Inflammatory (count) Baseline counts: 57 (Target) / 54 (Comparator)	Mid (12)	Percent Change*: -51	*.001*	Percent Change*: -57	*.001*	**NS***
		Non-inflammatory (count) Baseline counts: 55 (Target) / 52 (Comparator)	Mid (12)	Percent Change*: -55	*.001*	Percent Change*: -44	*.001*	**NS***
		Severity (leeds)	Mid (12)	Measure: 0 (0.4)	*.001*	Measure: 0 (0.5)	*.001*	**NS***
	N.08.03			**Erythromycin + zinc**		**Clindamycin phosphate**		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
300 Parallel	N=103 Mod	**Comedones change (%)** Count location: Face.	Short (6)	Percent change: -65	*sig*	Percent change: -55	*sig*	**0.01**
		Severity change (cook %)	Short (6)	Measure: -50	*sig*	Measure: -30	*sig*	**0.001**
		Total inflammatory change (%)	Short (6)	Percent change: -60	*sig*	Percent change: -40	*sig*	**0.05**
		Comedones change (%)	Mid (12)	Percent change: -75	*sig*	Percent change: -65	*sig*	**NS**
		Severity change (cook %)	Mid (12)	Measure: -60	*sig*	Measure: -50	*sig*	**NS**
		Total inflammatory change (%)	Mid (12)	Percent change: -65	*sig*	Percent change: -55	*sig*	**0.05**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.